{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:49:42Z","timestamp":1772135382492,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Eicosanoids are key players in inflammatory diseases and cancer. Targeting their production by inhibiting Group IVA cytosolic phospholipase A\n                    <jats:sub>2<\/jats:sub>\n                    (cPLA\n                    <jats:sub>2<\/jats:sub>\n                    \u03b1) offers a promising approach for cancer therapy. In this study, we synthesize a second generation of thiazolyl ketone inhibitors of cPLA\n                    <jats:sub>2<\/jats:sub>\n                    \u03b1 starting with compound GK470 (AVX235) and test their in vitro and cellular activities. We identify a more potent and selective lead molecule, GK420 (AVX420), which we test in parallel with AVX235 and a structurally unrelated compound, AVX002 for inhibition of cell viability across a panel of cancer cell lines. From this, we show that activity of polycomb group repressive complex 2 is a key molecular determinant of sensitivity to cPLA\n                    <jats:sub>2<\/jats:sub>\n                    \u03b1 inhibition, while resistance depends on antioxidant response pathways. Consistent with these results, we show that elevated intracellular reactive oxygen species and activating transcription factor 4 target gene expression precede cell death in AVX420-sensitive T-cell acute lymphoblastic leukemia cells. Our findings imply cPLA\n                    <jats:sub>2<\/jats:sub>\n                    \u03b1 may support cancer by mitigating oxidative stress and inhibiting tumor suppressor expression and suggest that AVX420 has potential for treating acute leukemias and other cancers that are susceptible to oxidative cell death.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-55536-9","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:50:48Z","timestamp":1735851048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 \u03b1 for targeted cancer therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7753-6408","authenticated-orcid":false,"given":"Felicity J.","family":"Ashcroft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asimina","family":"Bourboula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"Mahammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrosini","family":"Barbayianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid J.","family":"Feuerherm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh Thuy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroula G.","family":"Kokotou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Alevizopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-3140","authenticated-orcid":false,"given":"Edward A.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-7082","authenticated-orcid":false,"given":"George","family":"Kokotos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-7614","authenticated-orcid":false,"given":"Berit","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"55536_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nri3859","volume":"15","author":"EA Dennis","year":"2015","unstructured":"Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 15, 511\u2013523 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"55536_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","volume":"294","author":"CD Funk","year":"2001","unstructured":"Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871\u20131875 (2001).","journal-title":"Science"},{"key":"55536_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct. Target Ther. 6, 94 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"55536_CR4","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","volume":"111","author":"EA Dennis","year":"2011","unstructured":"Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V. & Kokotos, G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 111, 6130\u20136185 (2011).","journal-title":"Chem. Rev."},{"key":"55536_CR5","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1194\/jlr.R057588","volume":"56","author":"CC Leslie","year":"2015","unstructured":"Leslie, C. C. Cytosolic phospholipase A2: physiological function and role in disease. J. lipid Res. 56, 1386\u20131402 (2015).","journal-title":"J. lipid Res."},{"key":"55536_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/17460441.2021.1942835","volume":"16","author":"CS Batsika","year":"2021","unstructured":"Batsika, C. S., Gerogiannopoulou, A. D., Mantzourani, C., Vasilakaki, S. & Kokotos, G. The design and discovery of phospholipase A(2) inhibitors for the treatment of inflammatory diseases. Expert Opin. Drug Discov. 16, 1287\u20131305 (2021).","journal-title":"Expert Opin. Drug Discov."},{"key":"55536_CR7","unstructured":"Wyeth. A study comparing four dose regimens of PLA-695, naproxen, and placebo in subjects with osteoarthritis of the knee. NCT00396955 (2006)."},{"key":"55536_CR8","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1021\/jm061131z","volume":"50","author":"KL Lee","year":"2007","unstructured":"Lee, K. L. et al. Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J. Med Chem. 50, 1380\u20131400 (2007).","journal-title":"J. Med Chem."},{"key":"55536_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1124\/jpet.111.186379","volume":"340","author":"CA Hewson","year":"2012","unstructured":"Hewson, C. A. et al. Preclinical evaluation of an inhibitor of cytosolic phospholipase A2\u03b1 for the treatment of asthma. J. Pharmacol. Exp. Ther. 340, 656\u2013665 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55536_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1124\/jpet.115.229906","volume":"356","author":"S Kanai","year":"2016","unstructured":"Kanai, S. et al. ASB14780, an orally active inhibitor of group IVA phospholipase A2, is a pharmacotherapeutic candidate for nonalcoholic fatty liver disease. J. Pharmacol. Exp. Ther. 356, 604\u2013614 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55536_CR11","doi-asserted-by":"publisher","first-page":"7244","DOI":"10.1021\/jm500494y","volume":"57","author":"T Tomoo","year":"2014","unstructured":"Tomoo, T. et al. Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2\u03b1 inhibitors. J. Med Chem. 57, 7244\u20137262 (2014).","journal-title":"J. Med Chem."},{"key":"55536_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1124\/jpet.118.255034","volume":"369","author":"H Shimizu","year":"2019","unstructured":"Shimizu, H. et al. AK106-001616, a potent and selective inhibitor of cytosolic phospholipase A(2): in vivo efficacy for inflammation, neuropathic pain, and pulmonary fibrosis. J. Pharmacol. Exp. Ther. 369, 511\u2013522 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55536_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/jm9905155","volume":"43","author":"K Seno","year":"2000","unstructured":"Seno, K. et al. Pyrrolidine inhibitors of human cytosolic phospholipase A(2). J. Med Chem. 43, 1041\u20131044 (2000).","journal-title":"J. Med Chem."},{"key":"55536_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbrc.2018.01.016","volume":"496","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases. Biochem. Biophys. Res. Commun. 496, 153\u2013158 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"55536_CR15","doi-asserted-by":"publisher","first-page":"e00280","DOI":"10.1128\/IAI.00280-17","volume":"85","author":"R Bhowmick","year":"2017","unstructured":"Bhowmick, R., Clark, S., Bonventre, J. V., Leong, J. M. & McCormick, B. A. Cytosolic phospholipase A(2)\u03b1 promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae Infection. Infect. Immun. 85, e00280\u201317 (2017).","journal-title":"Infect. Immun."},{"key":"55536_CR16","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1021\/jm0613673","volume":"50","author":"DA Six","year":"2007","unstructured":"Six, D. A. et al. Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2. J. Med. Chem. 50, 4222\u20134235 (2007).","journal-title":"J. Med. Chem."},{"key":"55536_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/jpet.105.091686","volume":"316","author":"TL Yaksh","year":"2006","unstructured":"Yaksh, T. L. et al. Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J. Pharmacol. Exp. Ther. 316, 466\u2013475 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55536_CR18","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1021\/jm051243a","volume":"49","author":"J Ludwig","year":"2006","unstructured":"Ludwig, J., Bovens, S., Brauch, C., Elfringhoff, A. S. & Lehr, M. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha. J. Med. Chem. 49, 2611\u20132620 (2006).","journal-title":"J. Med. Chem."},{"key":"55536_CR19","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1021\/jm500192s","volume":"57","author":"G Kokotos","year":"2014","unstructured":"Kokotos, G. et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J. Med. Chem. 57, 7523\u20137535 (2014).","journal-title":"J. Med. Chem."},{"key":"55536_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang, D. & Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181\u2013193 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"55536_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2020.10.021","volume":"497","author":"Z Peng","year":"2021","unstructured":"Peng, Z., Chang, Y., Fan, J., Ji, W. & Su, C. Phospholipase A2 superfamily in cancer. Cancer Lett. 497, 165\u2013177 (2021).","journal-title":"Cancer Lett."},{"key":"55536_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.bjc.6606025","volume":"104","author":"F Caiazza","year":"2011","unstructured":"Caiazza, F. et al. Cytosolic phospholipase A2-\u03b1 expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. Br. J. Cancer 104, 338\u2013344 (2011).","journal-title":"Br. J. Cancer"},{"key":"55536_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3597","volume":"16","author":"MT Grinde","year":"2014","unstructured":"Grinde, M. T. et al. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res. 16, R5 (2014).","journal-title":"Breast Cancer Res."},{"key":"55536_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2225-1","volume":"16","author":"E Kim","year":"2016","unstructured":"Kim, E. et al. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer 16, 191 (2016).","journal-title":"BMC Cancer"},{"key":"55536_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.cell.2020.05.053","volume":"181","author":"N Koundouros","year":"2020","unstructured":"Koundouros, N. et al. Metabolic fingerprinting links oncogenic PIK3CA with enhanced arachidonic acid-derived eicosanoids. Cell 181, 1596\u20131611.e1527 (2020).","journal-title":"Cell"},{"key":"55536_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/dna.2019.5187","volume":"39","author":"H Bai","year":"2020","unstructured":"Bai, H., Zhou, M., Zeng, M. & Han, L. PLA2G4A is a potential biomarker predicting shorter overall survival in patients with non-M3\/NPM1 wildtype acute myeloid leukemia. DNA Cell Biol. 39, 700\u2013708 (2020).","journal-title":"DNA Cell Biol."},{"key":"55536_CR27","doi-asserted-by":"publisher","first-page":"e1004068","DOI":"10.1371\/journal.pcbi.1004068","volume":"11","author":"K Fortney","year":"2015","unstructured":"Fortney, K. et al. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data. PLoS Comput. Biol. 11, e1004068 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"55536_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-021-00888-0","volume":"14","author":"Y Lai","year":"2021","unstructured":"Lai, Y. et al. Novel prognostic genes and subclasses of acute myeloid leukemia revealed by survival analysis of gene expression data. BMC Med Genomics 14, 39 (2021).","journal-title":"BMC Med Genomics"},{"key":"55536_CR29","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/jnci\/djq290","volume":"102","author":"AG Linkous","year":"2010","unstructured":"Linkous, A. G., Yazlovitskaya, E. M. & Hallahan, D. E. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J. Natl Cancer Inst. 102, 1398\u20131412 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"55536_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/neuonc\/noaa255","volume":"23","author":"K Yi","year":"2020","unstructured":"Yi, K. et al. PTRF\/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2. Neuro-Oncol. 23, 387\u2013399 (2020).","journal-title":"Neuro-Oncol."},{"key":"55536_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2011.02.015","volume":"304","author":"RR Schulte","year":"2011","unstructured":"Schulte, R. R., Linkous, A. G., Hallahan, D. E. & Yazlovitskaya, E. M. Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett. 304, 137\u2013143 (2011).","journal-title":"Cancer Lett."},{"key":"55536_CR32","doi-asserted-by":"publisher","first-page":"e69688","DOI":"10.1371\/journal.pone.0069688","volume":"8","author":"D Thotala","year":"2013","unstructured":"Thotala, D. et al. Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models. PloS one 8, e69688 (2013).","journal-title":"PloS one"},{"key":"55536_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/15384047.2019.1579961","volume":"20","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing \u03b2-catenin signaling. Cancer Biol. Ther. 20, 912\u2013921 (2019).","journal-title":"Cancer Biol. Ther."},{"key":"55536_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"55536_CR35","doi-asserted-by":"crossref","unstructured":"Holmeide, A. K. & Skatteb\u00f8l, L. Syntheses of some polyunsaturated trifluoromethyl ketones as potential phospholipase A2 inhibitors. J. Chem. Soc. Perkin Trans. 1, 2271\u20132276 (2000).","DOI":"10.1039\/b001944p"},{"key":"55536_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","volume":"81","author":"KD Paull","year":"1989","unstructured":"Paull, K. D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst. 81, 1088\u20131092 (1989).","journal-title":"J. Natl Cancer Inst."},{"key":"55536_CR37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nmeth.2651","volume":"10","author":"M Hofree","year":"2013","unstructured":"Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108\u20131115 (2013).","journal-title":"Nat. Methods"},{"key":"55536_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","volume":"14","author":"A Laugesen","year":"2014","unstructured":"Laugesen, A. & Helin, K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14, 735\u2013751 (2014).","journal-title":"Cell Stem Cell"},{"key":"55536_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao, R. C. & Dou, Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer 15, 334\u2013346 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"55536_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"55536_CR41","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55536_CR42","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/onc.2012.47","volume":"32","author":"ZH Wen","year":"2013","unstructured":"Wen, Z. H. et al. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. Oncogene 32, 160\u2013170 (2013).","journal-title":"Oncogene"},{"key":"55536_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109\u2013116 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"55536_CR44","doi-asserted-by":"publisher","first-page":"e100559","DOI":"10.1371\/journal.pone.0100559","volume":"9","author":"T Okumura","year":"2014","unstructured":"Okumura, T. et al. Phospholipase C-related catalytically inactive protein (PRIP) regulates lipolysis in adipose tissue by modulating the phosphorylation of hormone-sensitive lipase. PloS one 9, e100559 (2014).","journal-title":"PloS one"},{"key":"55536_CR45","doi-asserted-by":"publisher","first-page":"1801862","DOI":"10.1002\/advs.201801862","volume":"6","author":"Z Xiong","year":"2019","unstructured":"Xiong, Z. et al. Tumor cell \u201cSlimming\u201d regulates tumor progression through PLCL1\/UCP1-mediated lipid browning. Adv. Sci. 6, 1801862 (2019).","journal-title":"Adv. Sci."},{"key":"55536_CR46","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jcp.31041","volume":"238","author":"J Cao","year":"2023","unstructured":"Cao, J., Zhou, A., Zhou, Z., Liu, H. & Jia, S. The role of GPLD1 in chronic diseases. J. Cell. Physiol. 238, 1407\u20131415 (2023).","journal-title":"J. Cell. Physiol."},{"key":"55536_CR47","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1152\/ajpendo.00698.2009","volume":"299","author":"MJ Watt","year":"2010","unstructured":"Watt, M. J. & Spriet, L. L. Triacylglycerol lipases and metabolic control: implications for health and disease. Am. J. Physiol.-Endocrinol. Metab. 299, E162\u2013E168 (2010).","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"55536_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","volume":"236","author":"K Itoh","year":"1997","unstructured":"Itoh, K. et al. An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313\u2013322 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"55536_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1021\/acs.chemrestox.6b00319","volume":"30","author":"TM Penning","year":"2017","unstructured":"Penning, T. M. Aldo-keto reductase regulation by the Nrf2 system: implications for stress response, chemotherapy drug resistance, and carcinogenesis. Chem. Res Toxicol. 30, 162\u2013176 (2017).","journal-title":"Chem. Res Toxicol."},{"key":"55536_CR50","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.3390\/molecules26247447","volume":"26","author":"N Mahammad","year":"2021","unstructured":"Mahammad, N. et al. Inhibition of cytosolic phospholipase A2\u03b1 induces apoptosis in multiple myeloma cells. Molecules 26, 7447 (2021).","journal-title":"Molecules"},{"key":"55536_CR51","doi-asserted-by":"publisher","first-page":"747837","DOI":"10.3389\/fphar.2021.747837","volume":"12","author":"X Tian","year":"2021","unstructured":"Tian, X. et al. Targeting the integrated stress response in cancer therapy. Front. Pharm. 12, 747837 (2021).","journal-title":"Front. Pharm."},{"key":"55536_CR52","doi-asserted-by":"publisher","first-page":"27023","DOI":"10.18632\/oncotarget.4809","volume":"6","author":"JC Tiffen","year":"2015","unstructured":"Tiffen, J. C. et al. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget 6, 27023\u201327036 (2015).","journal-title":"Oncotarget"},{"key":"55536_CR53","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","volume":"6","author":"H Xie","year":"2016","unstructured":"Xie, H. et al. Chronic myelogenous leukemia\u2014initiating cells require polycomb group protein EZH2. Cancer Discov. 6, 1237\u20131247 (2016).","journal-title":"Cancer Discov."},{"key":"55536_CR54","doi-asserted-by":"publisher","first-page":"36393","DOI":"10.1074\/jbc.M112.399600","volume":"287","author":"J Shan","year":"2012","unstructured":"Shan, J., Fu, L., Balasubramanian, M. N., Anthony, T. & Kilberg, M. S. ATF4-dependent regulation of the JMJD3 gene during amino acid deprivation can be rescued in Atf4-deficient cells by inhibition of deacetylation. J. Biol. Chem. 287, 36393\u201336403 (2012).","journal-title":"J. Biol. Chem."},{"key":"55536_CR55","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.1073\/pnas.1906275116","volume":"116","author":"RA Panganiban","year":"2019","unstructured":"Panganiban, R. A. et al. Genome-wide CRISPR screen identifies suppressors of endoplasmic reticulum stress-induced apoptosis. Proc. Natl Acad. Sci. USA 116, 13384\u201313393 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55536_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.gene.2016.03.058","volume":"586","author":"F Katsuoka","year":"2016","unstructured":"Katsuoka, F. & Yamamoto, M. Small Maf proteins (MafF, MafG, MafK): history, structure and function. Gene 586, 197\u2013205 (2016).","journal-title":"Gene"},{"key":"55536_CR57","doi-asserted-by":"publisher","first-page":"e0052021","DOI":"10.1128\/mcb.00520-21","volume":"42","author":"F Katsuoka","year":"2022","unstructured":"Katsuoka, F., Otsuki, A., Hatanaka, N., Okuyama, H. & Yamamoto, M. Target gene diversity of the Nrf1-MafG transcription factor revealed by a tethered heterodimer. Mol. Cell Biol. 42, e0052021 (2022).","journal-title":"Mol. Cell Biol."},{"key":"55536_CR58","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1152\/physrev.00005.2017","volume":"97","author":"C Siebel","year":"2017","unstructured":"Siebel, C. & Lendahl, U. Notch signaling in development, tissue homeostasis, and disease. Physiol. Rev. 97, 1235\u20131294 (2017).","journal-title":"Physiol. Rev."},{"key":"55536_CR59","doi-asserted-by":"publisher","first-page":"27369","DOI":"10.1074\/jbc.M800696200","volume":"283","author":"A Gubern","year":"2008","unstructured":"Gubern, A. et al. Group IVA phospholipase A2 is necessary for the biogenesis of lipid droplets. J. Biol. Chem. 283, 27369\u201327382 (2008).","journal-title":"J. Biol. Chem."},{"key":"55536_CR60","doi-asserted-by":"publisher","first-page":"32359","DOI":"10.1074\/jbc.M109.061515","volume":"284","author":"A Gubern","year":"2009","unstructured":"Gubern, A. et al. JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A2. J. Biol. Chem. 284, 32359\u201332369 (2009).","journal-title":"J. Biol. Chem."},{"key":"55536_CR61","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.3390\/cancers15164100","volume":"15","author":"D Delmas","year":"2023","unstructured":"Delmas, D. et al. Emergence of lipid droplets in the mechanisms of carcinogenesis and therapeutic responses. Cancers 15, 4100 (2023).","journal-title":"Cancers"},{"key":"55536_CR62","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/biomedicines11123186","volume":"11","author":"C Nistic\u00f2","year":"2023","unstructured":"Nistic\u00f2, C. & Chiarella, E. An overview on lipid droplets accumulation as novel target for acute myeloid leukemia therapy. Biomedicines 11, 3186 (2023).","journal-title":"Biomedicines"},{"key":"55536_CR63","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbabio.2010.10.022","volume":"1807","author":"LS Pike","year":"2011","unstructured":"Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A. & Wu, M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726\u2013734 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"55536_CR64","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbalip.2018.08.009","volume":"1864","author":"A Nikolaou","year":"2019","unstructured":"Nikolaou, A., Kokotou, M. G., Vasilakaki, S. & Kokotos, G. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2. Biochim. Biophys. Acta Mol. Cell Biol.Lipids 1864, 941\u2013956 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol.Lipids"},{"key":"55536_CR65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","volume":"13","author":"A Carracedo","year":"2013","unstructured":"Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227\u2013232 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"55536_CR66","doi-asserted-by":"publisher","first-page":"115550","DOI":"10.1016\/j.bcp.2023.115550","volume":"212","author":"B Chakravarti","year":"2023","unstructured":"Chakravarti, B., Akhtar Siddiqui, J., Anthony Sinha, R. & Raza, S. Targeting autophagy and lipid metabolism in cancer stem cells. Biochem. Pharmacol. 212, 115550 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"55536_CR67","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","volume":"20","author":"EM Michalak","year":"2019","unstructured":"Michalak, E. M., Burr, M. L., Bannister, A. J. & Dawson, M. A. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat. Rev. Mol. Cell Biol. 20, 573\u2013589 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"55536_CR68","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. M. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"55536_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01045-1","volume":"13","author":"C Li","year":"2021","unstructured":"Li, C. et al. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors. Clin. Epigenetics 13, 62 (2021).","journal-title":"Clin. Epigenetics"},{"key":"55536_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10681-4","volume":"10","author":"HW Smith","year":"2019","unstructured":"Smith, H. W. et al. An ErbB2\/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nat. Commun. 10, 2901 (2019).","journal-title":"Nat. Commun."},{"key":"55536_CR71","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1080\/15548627.2015.1117734","volume":"11","author":"FZ Wei","year":"2015","unstructured":"Wei, F. Z. et al. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 11, 2309\u20132322 (2015).","journal-title":"Autophagy"},{"key":"55536_CR72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo, B. et al. ROS in cancer therapy: the bright side of the moon. Exp. Mol. Med. 52, 192\u2013203 (2020).","journal-title":"Exp. Mol. Med."},{"key":"55536_CR73","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1002\/jcp.28091","volume":"234","author":"LXT Nguyen","year":"2019","unstructured":"Nguyen, L. X. T. et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J. Cell. Physiol. 234, 14040\u201314049 (2019).","journal-title":"J. Cell. Physiol."},{"key":"55536_CR74","doi-asserted-by":"publisher","first-page":"216352","DOI":"10.1016\/j.canlet.2023.216352","volume":"572","author":"J Qin","year":"2023","unstructured":"Qin, J. et al. Fatty acids in cancer chemoresistance. Cancer Lett. 572, 216352 (2023).","journal-title":"Cancer Lett."},{"key":"55536_CR75","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens, B. M. et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Cancer 1, 1176\u20131187 (2020).","journal-title":"Nat. Cancer"},{"key":"55536_CR76","doi-asserted-by":"publisher","first-page":"30527","DOI":"10.1074\/jbc.M008481200","volume":"276","author":"MW Anthonsen","year":"2001","unstructured":"Anthonsen, M. W., Solhaug, A. & Johansen, B. Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-\u03b1- and interleukin-1\u03b2-induced NF-\u03baB activation. J. Biol. Chem. 276, 30527\u201330536 (2001).","journal-title":"J. Biol. Chem."},{"key":"55536_CR77","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1021\/acs.jmedchem.6b00377","volume":"59","author":"VD Mouchlis","year":"2016","unstructured":"Mouchlis, V. D. et al. Development of potent and selective inhibitors for group VIA calcium-independent phospholipase A2 guided by molecular dynamics and structure-activity relationships. J. Med. Chem. 59, 4403\u20134414 (2016).","journal-title":"J. Med. Chem."},{"key":"55536_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0092-8674(00)80744-8","volume":"97","author":"A Dessen","year":"1999","unstructured":"Dessen, A. et al. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 97, 349\u2013360 (1999).","journal-title":"Cell"},{"key":"55536_CR79","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","volume":"35","author":"EL Wu","year":"2014","unstructured":"Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J. Comput Chem. 35, 1997\u20132004 (2014).","journal-title":"J. Comput Chem."},{"key":"55536_CR80","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 12, 405\u2013413 (2016).","journal-title":"J. Chem. Theory Comput."},{"key":"55536_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"55536_CR82","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1021\/ml100164p","volume":"1","author":"K Stierand","year":"2010","unstructured":"Stierand, K. & Rarey, M. Drawing the PDB: protein-ligand complexes in two dimensions. ACS Med. Chem. Lett. 1, 540\u2013545 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"55536_CR83","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).","journal-title":"Nucleic Acids Res."},{"key":"55536_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-2836(84)90309-7","volume":"179","author":"D Eisenberg","year":"1984","unstructured":"Eisenberg, D., Schwarz, E., Komaromy, M. & Wall, R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 179, 125\u2013142 (1984).","journal-title":"J. Mol. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55536-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55536-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55536-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T10:03:14Z","timestamp":1735898594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55536-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55536"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55536-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3485987\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.F., B.J., F.J.A., E.A.D., and G.K. are shareholders, while F.J.A. and N.M. were employees of Coegin Pharma at the time of results generation. The other authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}